Cargando…
SARS-CoV-2 vaccine development, access, and equity
Over the past 9 mo, with 34 million infections and 1 million deaths, the COVID-19 pandemic has levied a grisly toll. Some countries, through political will and social organization, have successfully reduced the number of infections and deaths, but the global scale of loss reflects the difficulty of...
Autor principal: | Kim, Jerome H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Rockefeller University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563686/ https://www.ncbi.nlm.nih.gov/pubmed/33064151 http://dx.doi.org/10.1084/jem.20201288 |
Ejemplares similares
-
Elimination versus mitigation of SARS-CoV-2 in the presence of effective vaccines
por: Oliu-Barton, Miquel, et al.
Publicado: (2022) -
EULAR December 2020 viewpoints on SARS-CoV-2 vaccination in patients with RMDs
por: Bijlsma, Johannes WJ
Publicado: (2021) -
SARS-CoV-2 Vaccination in India: Considerations of Hesitancy and Bioethics in Global Health
por: Sarkar, Mohammad Abdullah, et al.
Publicado: (2021) -
COVID-19 and SARS-CoV-2 Vaccines: A Cameo Role for Headache
por: Martelletti, Paolo
Publicado: (2023) -
Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs
por: Dzinamarira, Tafadzwa, et al.
Publicado: (2022)